FDA Approves Neoadjuvant and Adjuvant Pembrolizumab for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma By Ogkologos - July 18, 2025 555 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the KEYNOTE-689 study Source RELATED ARTICLESMORE FROM AUTHOR Noninferiority of OS with 3 Months Compared to 6 Months of Adjuvant Chemotherapy for Patients with High-Risk Stage III Colorectal Cancer Patient Guide on Bone Health in Cancer Now Available Also in French Lung Cancer Death Rates Among Women in Europe Are Finally Levelling Off MOST POPULAR Progress in Treating Liver Cancer and Biliary Tract Cancer with Immunotherapy:... January 18, 2022 Program Connects Adolescents and Young Adults to Quality Cancer Care October 24, 2024 How the history of medicine influenced our perception of cancer October 13, 2022 Postoperative Radioiodine Can Be Avoided in Patients with Low-Risk Differentiated Thyroid... August 12, 2025 Load more HOT NEWS After Struggling With Chronic Illnesses Most of Her Life, This Author... Tarlatamab Shows Promise in Patients with Previously Treated Small-Cell Lung Cancer FDA Approves Pembrolizumab with Chemotherapy for Primary Advanced or Recurrent Endometrial... 20 years on: how we’ve decreased cancer death rates
